VANCOUVER, British Columbia – ME Therapeutics Holdings Inc. (“ME Therapeutics”), a preclinical biotechnology company focused on innovative immuno-oncology drugs, announced today that its subsidiary, ME Therapeutics Inc., will receive advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
This funding will support the research and development of ME Therapeutics’ mRNA therapeutic program, which targets myeloid cell biology for the treatment of cancer and inflammatory diseases.
“We’re thrilled to receive this continued support from NRC IRAP, which builds on previous advisory services and funding,” said Salim Dhanji, CEO of ME Therapeutics. “This will allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways.”
Dhanji emphasized the company’s belief in the potential of these therapies: “Our team passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who currently have limited options. We’re committed to bringing these potential new approaches to the clinic as soon as possible.”
ME Therapeutics has engineered proprietary mRNA sequences to encode proteins that can precisely modify the immune response in vivo. Their lead mRNA therapeutic candidate is designed to modulate immune cells within the tumor microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already shown encouraging anti-cancer activity in a mouse model of colorectal cancer. The company is also exploring modifications to its mRNA candidates to achieve tissue-specific mRNA expression, aiming for increased efficacy and safety.
Source:
https://www.biospace.com/press-releases/me-therapeutics-receives-support-to-advance-mrna-therapeutic-candidates-for-cancer-and-inflammatory-disease
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
